VistaGen Therapeutics, Inc.
NASDAQ Capital MarketTotal Valuation
VistaGen Therapeutics, Inc. carries a market capitalization of 12.47M, placing it among publicly traded companies globally. Its enterprise value stands at -20.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.47M |
| Enterprise Value | -20.92M |
Share Statistics
VistaGen Therapeutics, Inc. currently has 44.38M shares outstanding.
| Shares Outstanding | 44.38M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 3.64, and the price-to-book ratio stands at 0.41.
| PE Ratio | N/A |
| PS Ratio | 3.64 |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.41 |
| P/FCF Ratio | -0.15 |
| P/OCF Ratio | -0.15 |
Enterprise Valuation
| EV / Sales | 87.04 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
VistaGen Therapeutics, Inc. maintains a current ratio of 3.07, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.07 |
| Quick Ratio | 2.84 |
| Debt / Equity | 3.20 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -166.46 |
| Return on Assets (ROA) | -129.22 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 7,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
VistaGen Therapeutics, Inc.'s stock has declined approximately -92.19444% over the past 52 weeks. The 50-day moving average sits at 0.26, while the 200-day moving average is 0.54.
| Beta (5Y) | N/A |
| 52-Week Price Change | -92.19444% |
| 50-Day Moving Average | 0.26 |
| 200-Day Moving Average | 0.54 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, VistaGen Therapeutics, Inc. generated 2.50M in revenue and converted that into -67.62M in net income, yielding earnings per share of -1.68. EBITDA reached -68.90M, while operating income came in at -69.66M.
| Revenue | 2.50M |
| Gross Profit | N/A |
| Operating Income | -69.66M |
| Pretax Income | -67.61M |
| Net Income | -67.62M |
| EBITDA | -68.90M |
| EBIT | -69.66M |
| Earnings Per Share (EPS) | -1.68 |
Balance Sheet
VistaGen Therapeutics, Inc. holds 31.73M in cash and equivalents against 783,000.00 in total debt, resulting in a net debt position of -16.99M. Total book value stands at 24.48M, with working capital of 23.12M providing operational flexibility.
| Cash & Cash Equivalents | 31.73M |
| Total Debt | 783,000.00 |
| Net Debt | -16.99M |
| Equity (Book Value) | 24.48M |
| Book Value Per Share | 0.55 |
| Working Capital | 23.12M |
Cash Flow
VistaGen Therapeutics, Inc. produced -62.30M in operating cash flow over the past twelve months. After subtracting -86,000.00 in capital expenditures, free cash flow totaled -62.38M - equivalent to -1.55 per share.
| Operating Cash Flow | -62.30M |
| Capital Expenditures | -86,000.00 |
| Free Cash Flow | -62.38M |
| FCF Per Share | -1.55 |
Margins
VistaGen Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -2,784.33 and net profit margin of -2,702.64 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -2,784.33 |
| Pretax Margin | -2,702.36 |
| Profit Margin | -2,702.64 |
| EBITDA Margin | -2,753.92 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -303.04 |
| FCF Yield | -682.69 |
Stock Splits
VistaGen Therapeutics, Inc.'s most recent stock split took place on June 7, 2023 with a 30:1 split ratio.
| Last Split Date | 6/7/2023 |
| Split Ratio | 30:1 |
Scores
VistaGen Therapeutics, Inc. posts an Altman Z-Score of -24.26, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -24.26 |